Carna Biosciences, Inc. (TYO:4572)

Japan flag Japan · Delayed Price · Currency is JPY
328.00
+13.00 (4.13%)
At close: Mar 6, 2026
Market Cap6.29B +13.2%
Revenue (ttm)579.06M -9.0%
Net Income-2.17B
EPS-113.62
Shares Out19.19M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume120,700
Average Volume223,315
Open313.00
Previous Close315.00
Day's Range310.00 - 335.00
52-Week Range200.00 - 512.00
Beta0.44
RSI48.99
Earnings DateFeb 10, 2026

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 63
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4572
Full Company Profile

Financial Performance

In 2025, Carna Biosciences's revenue was 579.06 million, a decrease of -8.95% compared to the previous year's 636.00 million. Losses were -2.17 billion, -0.30% less than in 2024.

Financial Statements